Using
the current years Dividend Growth rate of 2 % and projecting 2 % forward the annual dividend income in 10 yrs would be $ 0.00 with a yield on cost % of 3.00 %
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full
year 2018 financial results; Gilead's ability to sustain
growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and
current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay
dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
This table shows the annual
rate of LAZ's
dividend growth since its
current streak of 10
years started.
In a fairly poor scenario, even if only a 5.7 % long - term EPS /
dividend growth rate is achieved (chosen to match the previous 7 -
year average EPS
growth), then the
current price in the low $ 80's can still offer a 9 % long - term
rate of return, based on the DDM again.
The
current yield of 1.55 % might not be massive like AT&T's
dividend (which is why we diversify, and it's why I'm listing 10 different stocks with different dynamics here), but Walt Disney more than makes up for that via strong
dividend growth: the five -
year dividend growth rate is 30.1 %, which is one of the higher
rates you'll run across.
If I assume a
dividend growth rate of 6 percent (about the long - run average *), the
current S&P 500
dividend yield of 2.1 percent (from multpl.com), a terminal S&P 500
dividend yield of 4 percent (Hussman says that the
dividend yield on stocks has historically averaged about 4 percent), the expected nominal return over ten
years is 2.4 percent annually.
As you can see many of the stocks mentioned may have high
current PE's but also feature long to very long
dividend histories with relatively high ten
year annualized
dividend growth rates at around or better than 10 %.
Finally, my
current favourite is Canadian Tire (CTC.A, $ 56.38), which pays a 1.5 %
dividend yield, sports a price - to - earnings ratio of 13.5, and a five -
year annual
dividend growth rate of 10.9 %.
They have a reasonable payout ratio of 49.5 %, the
current yield is a very healthy 3.4 % and the 5
year dividend growth rate is 5.8 % (6.9 % if we count 2015, see below).
Assuming that the
current dividend payout ratios and earnings
growth rates stay approximately constant in the future, the ETF should return about 11 % per
year in total.
While I wouldn't expect that kind of
dividend growth to continue on for the foreseeable future, as much of this
growth was propelled by a growing payout ratio, the
current payout ratio of 45.3 % still leaves a lot of room for continued
dividend increases, even increases that exceed the
rate of underlying profit
growth for the next few
years.
The
current yield of 1.55 % might not be massive like AT&T's
dividend (which is why we diversify, and it's why I'm listing 10 different stocks with different dynamics here), but Walt Disney more than makes up for that via strong
dividend growth: the five -
year dividend growth rate is 30.1 %, which is one of the higher
rates you'll run across.
- Seven
Year Revenue
Growth Rate: 5.8 % - Seven
Year EPS
Growth Rate: 9.4 % - Seven
Year Dividend Growth Rate: 14.9 % -
Current Dividend Yield: 2.43 % - Balance Sheet: Reasonable Leverage, Stable Currently, Walmart's $ 77 share price appears to be fairly valued for an expectation of 10 % long - term returns.
If I assume a
dividend growth rate of 6 percent (about the long - run average *), the
current S&P 500
dividend yield of 2.1 percent (from multpl.com), a terminal S&P 500
dividend yield of 4 percent (Hussman says that the
dividend yield on stocks has historically averaged about 4 percent), the expected nominal return over ten
years is 2.4 percent annually.
- Seven
Year Revenue
Growth Rate: 10.5 %
Dividend Stock Report - Seven
Year EPS
Growth Rate: 7.3 % - Seven
Year Dividend Growth Rate: 11.2 % -
Current Dividend Yield: 2.84 % - Balance Sheet: Stable
With a
dividend growth compound annual
growth rate of 16.95 % and 18.37 % over the last 10 and 5
years, respectively, this stock is a fantastic buy at
current prices.
Five
Year Revenue
Growth: < 1 % EPS
Growth: Low or Negative Five
Year Growth of Book Value: 7 %
Dividend Yield: 5.64 % Five Year Annual Dividend Growth Rate: 15 % Price - to - Book: 0.93 I find HGIC to be a solid value at the current price, with a sustainable and large dividend yield, and a solid financial co
Dividend Yield: 5.64 % Five
Year Annual
Dividend Growth Rate: 15 % Price - to - Book: 0.93 I find HGIC to be a solid value at the current price, with a sustainable and large dividend yield, and a solid financial co
Dividend Growth Rate: 15 % Price - to - Book: 0.93 I find HGIC to be a solid value at the
current price, with a sustainable and large
dividend yield, and a solid financial co
dividend yield, and a solid financial condition.
The long - term
growth rate has been something like 12 % a
year and the
current dividend yield is just below 5 %.